Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 981-985

  Takeda, Jun ^a   Kitajima, Kazuaki ^a   Fujii, Shigehiko ^a   Horiuchi, Hideki ^a   Hori, Hiroshige ^a   Chibana, Yoko ^a   Okuyama, Takashi ^a   Tominaga, Keiichi ^a   Ichikawa, Kazuhito ^a   Ono, Yuko ^a   Teramoto, Tadahisa ^a   Ohkura, Yasuo ^a   Imura, Joji ^a   Shinoda, Motoo ^a   Chiba, Tsutomu ^b   Sakamoto, Choitsu ^c   Kawamata, Hitoshi ^a   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Aberrant crypt foci; Colitis induced tumorigenesis; Cyclooxygenase 2 inhibitor; UC associated neoplasia; Ulcerative colitis (UC)

Indexed keywords

ETODOLAC; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; ARTICLE; COLITIS; COLON TUMOR; DISEASE MODEL; DRUG EFFECT; INTESTINE; PATHOLOGY; RAT;

ANIMALS; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; ETODOLAC; INTESTINES; RATS;

EID: 16544375256     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.981     Document Type: Article

References (24)

1. Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993. (Pubitemid 23249348)
2. Thun MJ, Namboodiri MM and Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
3. Smalley W and DuBois RN: Colorectal cancer and non steroidal anti-inflammatory drugs. Adv Pharmacol 39: 1-20, 1997.
4. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-612, 1995.
5. Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CWJ: Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327, 1993. (Pubitemid 23097110)
6. Giovannucci E, Rimm EB, Stampfer MJ, Ciolditz GA, Ascherio A and Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246, 1994.
7. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993. (Pubitemid 23131373)
8. Waddel WR and Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983.
9. Waddel WR, Gasner GF, Cerise EJ and Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157: 175-178, 1989.
10. Ekbom A, Helmick C, Zack M and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233, 1990. (Pubitemid 20366527)
11. Fujii S, Fujimori T and Kashida H: Ulcerative colitis-associated neoplasia. Pathol Int 52: 195-203, 2002. (Pubitemid 36114828)
12. Furihata T, Kawamata H, Kubota K and Fujimori T: Evaluation of the malignant potential of aberrant crypt foci by immunohistochemical staining for beta-catenin in inflammation-induced rat colon carcinogenesis. Int J Mol Med 9: 353-358, 2002.
13. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR and Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803, 1989. (Pubitemid 19057602)
14. Elson CO, Sartor RB, Tennyson GS and Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
15. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151, 1987.
16. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR and Morson BC: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14: 931-968, 1983.
17. Lamrani A, Tulliez M, Chauvelot-Moachon L, Chaussade S, Mauprivez C, Hagnere AM and Vidon N: Effects of octreotide treatment on early TNF-alpha production and localization in experimental chronic colitis. Aliment Pharmacol Ther 13: 583-594, 1999. (Pubitemid 29219023)
18. Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H and Moilanen E: Induction of iNOS in a rat model of acute colitis. Inflammation 23: 141-152, 1999. (Pubitemid 29178602)
19. Macdonald TT: Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease. Gut 42: 460-461, 1998.
20. Suzuki M, Yoshimi N, Ushijima T, Hirose Y, Makita H, Wang A, Kawamori T, Tanaka T, Mori H and Nagao M: No involvement of Ki-ras or p53 gene mutations in colitis-associated rat colon tumors induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. Mol Carcinog 12: 193-197, 1995.
21. Okayasu I, Ohkusa T, Kajiura K, Kanno J and Sakamoto S: Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87-92, 1996. (Pubitemid 26239112)
22. Reddy BS, Rao CV and Seibert K: Evaluation of cyclooxy-genase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56: 4566-4569, 1996. (Pubitemid 26338047)
23. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM: Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996. (Pubitemid 26404280)
24. Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kwasaki H and Hasegawa J: Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Gut 47: 812-819, 2000.